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Abstract
Background: Tumor associated fibroblasts (TAF), are essential for tumor progression providing both a functional and
structural supportive environment. TAF, known as activated fibroblasts, have an established biological impact on
tumorigenesis as matrix synthesizing or matrix degrading cells, contractile cells, and even blood vessel associated cells. The
production of growth factors, cytokines, chemokines, matrix-degrading enzymes, and immunomodulatory mechanisms by
these cells augment tumor progression by providing a suitable environment. There are several suggested origins of the TAF
including tissue-resident, circulating, and epithelial-to-mesenchymal-transitioned cells.
Methodology/Principal Findings: We provide evidence that TAF are derived from mesenchymal stem cells (MSC) that
acquire a TAF phenotype following exposure to or systemic recruitment into adenocarcinoma xenograft models including
breast, pancreatic, and ovarian. We define the MSC derived TAF in a xenograft ovarian carcinoma model by the
immunohistochemical presence of 1) fibroblast specific protein and fibroblast activated protein; 2) markers phenotypically
associated with aggressiveness, including tenascin-c, thrombospondin-1, and stromelysin-1; 3) production of pro-
tumorigenic growth factors including hepatocyte growth factor, epidermal growth factor, and interleukin-6; and 4) factors
indicative of vascularization, including alpha-smooth muscle actin, desmin, and vascular endothelial growth factor. We
demonstrate that under long-term tumor conditioning in vitro, MSC express TAF–like proteins. Additionally, human MSC but
not murine MSC stimulated tumor growth primarily through the paracrine production of secreted IL6.
Conclusions/Significance: Our results suggest the dependence of in vitro Skov-3 tumor cell proliferation is due to the
presence of tumor-stimulated MSC secreted IL6. The subsequent TAF phenotype arises from the MSC which ultimately
promotes tumor growth through the contribution of microvascularization, stromal networks, and the production of tumor-
stimulating paracrine factors.
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Introduction
Tumor cells are not self-sustaining entities, but interact via
paracrine and juxtacrine signaling with the microenvironment.
Among the cells found in this stromal environment are
macrophages, endothelial cells, lymphocytes, fibroblasts, and
pericytes which interact with tumor cells and the surrounding
microenvironment through production of hormones, cytokines,
chemokines and proteases. Tumors are thought to develop stroma
from several sources, thus the characterization by Wels et al. of
tumor-associated stromal cells as ‘‘migratory neighbors and distant
invaders’’ [1]. Data in the literature currently support four origins:
(1) the recruitment of resident tissue stem cells, (2) epithelial to
mesenchymal transition of the tumor parenchyma, (3) fibroblast
recruitment into the tumor stroma, and (4) recruitment of bone
marrow-derived cells from the circulation [2–5].
We postulated that mesenchymal stem cells (MSC), like other
bone marrow-resident cells, have the capacity to differentiate
within the tumor microenvironment into fibroblastic-like cells that
have been variably referred to as; myofibroblasts, tumor-associated
(myo)fibroblasts (TAF), carcinoma-associated fibroblasts (CAF),
fibrocytes or pericytes [6]. TAF have been shown to play an
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presence of fibroblast populations within human tumors is
associated with poor outcome and an increase in metastatic
potential [7,8]. These TAF are associated with expression of
factors involved in degradation of matrix proteins, angiogenesis
and promotion of cell growth: matrix metalloproteinases (MMP),
plasminogen activator inhibitor-1, vascular endothelial growth
factor (VEGF), insulin growth factor (IGF-2) and hepatocyte
growth factor (HGF) [9]. The TAF population differs from a
normal fibroblastic phenotype because of its rich source of tumor-
growth-promoting factors, pro-angiogenic factors and expression
of myofibroblastic characteristics. TAF are characterized by the
presence of four qualifying factors: (1) fibroblast markers
fibroblast-specific protein (FSP) and fibroblast activating protein
(FAP); (2) genes associated with an increase of tumor aggression,
including stromelysin-1 (SL-1), thrombospondin-1 (Tsp-1) and
tenascin-C (Tn-C); (3) myofibroblast/provascularizing potential
including desmin, alpha-smooth muscle actin (a-SMA), and
vascular endothelial growth factor (VEGF) [10]; and lastly, (4)
growth factors, transforming growth factor-beta (TGF-b), HGF/
scatter factor (SF), basic fibroblast growth factor (bFGF) and
epidermal growth factor (EGF).
MSC comprise a unique population of cells utilized for tissue
maintenance and repair; their regenerative ability and multipotent
capacity allow for their differentiation into osteocytes, adipocytes,
chondrocytes, or myocytes. Importantly, MSC possess an innate
tropism for injured tissue. Our group originally demonstrated the
capacity of MSC, also known as multipotent stromal cells, to home
to tumors and participate in tumor stroma formation, suggesting
MSC as a potential source of stroma [11,12]. MSC are a
heterogeneous population of connective tissues progenitors found
in many locations, such as adipose tissue, dermis, and bone
marrow. The tropism of MSC for tumors is thought to be due to
similarity in factors secreted by wounds and tumors [13],
substantiating the concept that tumors are ‘‘wounds that never
heal’’ [14,15]. It has been proposed that this tropism could be
exploited by using MSC as gene-delivery vehicles for anticancer
therapies, and this approach has shown promise in preclinical
models [11,12,16–19]. The ability of MSC to travel to solid
tumors after intravenous administration and their ability to
develop myofibroblast-like characteristics under defined culture
conditions [20] both suggest that TAF could be derived from
MSC.
Our study was designed to assess whether MSC are precursors
of TAF-like cells in tumors and to analyze the contribution of
MSC to the growth and development of tumor fibrovascular
networks. We show herein the propensity of MSC to transition
within a xenograft tumor model to TAF-like cells and, by
immunohistochemical (IHC) staining, their tumor-supportive
nature. In a murine tumor xenograft model, human tumors with
admixed human MSC demonstrated cells expressing activated
fibroblast-like markers including FAP, FSP, a-SMA, Tn-C, Tsp-1,
desmin or SL-1, while tumors without admixed MSC did not show
these markers. The presence of MSC within the tumor also
enhanced expression of growth factors such as EGF and HGF. We
further demonstrate that the microenvironment provided by the
tumor stimulated MSC directly to enhance the growth of Skov-3,
which is significantly enhanced by growth factors interleukin-6 (IL-
6) and EGF.
Our data suggest the involvement of the MSC as a component
of tumor associated fibrovascular networks—this includes the
pericytic population that contributes to the microvessel involved in
the neovacularization as well as the fibroblastic population that
contributes to matrix remodeling and tumor growth. To our
knowledge is the first-in-kind report to demonstrate four levels of
tumor support by MSC in the tumor microenvironment: 1) matrix
formation, 2) growth factor production, 3) vasculogenesis/
angiogenesis and 4) expression of proteins associated with tumor
aggression.
Results
Defining TAFs in the context of MSC
The MSC population used in our investigation was character-
ized by flow cytometry and by western blot, prior to our in vivo
analysis of the MSC. We were able to induce a TAF phenotype in
vitro by conditioning MSC with Skov-3 conditioned medium over a
period of 16 days. Naı ¨ve MSC expressed low levels of a-SMA,
FAP and desmin and did not express the TAF markers FSP, TSP-
1 or Tn-C (Figure 1A): they were positive for the MSC markers
CD105, CD90, CD44, CD146, CD140b and CD166 and negative
for hematopoietic and endothelial markers CD31, CD34 and
CD45 (Figure S1). Following 16 days of in vitro conditioning with
Skov-3 cell medium the MSC express high levels of Tn-C, TSP
and FSP and increased their expression of a-SMA, FAP and
desmin.
We define a TAF by four characteristics that are outlined in
Figure 1B, these include fibroblast surface proteins (FAP and
FSP), proteins indicative of invasion and remodeling (TSP1, Tn-C,
SL-1), proteins associated with neovascularization (a-SMA,
desmin and VEGF), and tumor promoting growth factors (HGF,
EGF and IL6). In the following sections, we provide in vivo
evidence of the expression of these factors only in tumors that have
an admixed population of MSC, thereby illustrating the MSC
involvement as a TAF within the tumor microenvironment.
TAF marker expression in tumors harboring MSC
To elucidate the role that MSC play within the tumor
microenvironment, we focused on the MSC once engrafted into
the tumor. huMSC were admixed at a 1:1 ratio with Skov-3 tumor
cells prior to intravenous injection. Tumor growth was monitored
for 91 days after injection of the admixed, or Skov-3 only cells.
The tumors were removed from the mice, snap frozen and sent for
tissue processing at day 91 (see methods section). To support our
hypothesis that MSC contribute to the TAF population within the
tumor microenvironment, we stained the admixed and Skov-3
only tumors sections for four different TAF characteristics:
fibroblast surface markers, markers of vascularization, markers of
invasiveness and aggressiveness and expression of tumor-promot-
ing growth factors (Figure 1B).
IHC of fibroblast surface protein expression was conducted on
tumor sections to identify the first TAF characteristic. FSP and
FAP staining was evident within the admixed tumors that received
MSC but not in the untreated controls (Figure 2A and 2B). The
FAP and FSP are not ubiquitously expressed in the stroma, but are
restricted to cells that we identify as TAF and are stained in an
unorganized, unparallel striated pattern. The admixed tumors
have, by day 91, a larger area of human stromal contribution
compared to the Skov-3 only tumors. While the murine stromal
contribution is present in all the tumors, it is negligible compared
to the human stromal component of the admixed Skov-3/MSC
tumors (data not shown).
We then examined the expression of proteins consistent with an
aggressive or invasive phenotype. Three molecules that are vital to
the pathophysiological extracellular matrix (ECM) structure, Tn-
C, Tsp-1 and SL-1, are secreted by fibroblast-like cells and
modulate the structural architecture of the tumor. While MSC do
not typically express these markers, the expression of all three
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microenvironment. Both TSP-1 and Tn-C expression patterns
were high throughout the tumor microenvironment (Figure 2C
and 2D). The staining of the TSP-1 and Tn-C associate with
many of the neovascular and microvascular lumen within the
tumor, a phenomenon consistent with one of the TAF cell
phenotypes, the pericyte. The presence of SL-1 was observed
primarily on the leading edge of the tumor mass consistent its
function as a proteolytic enzyme (Figure 2E). These markers were
not expressed, however, in Skov-3 tumors that had not been
admixed with MSC.
The third characteristic of TAF is the expression of myofibro-
blast-like cell markers, including a-SMA, desmin and another
marker of neo-microvascularization, VEGF. In our admixed Skov-
3/MSC tumors, IHC staining revealed elaborate looped and
branched pattern arrangement of both a-SMA and desmin
(Figure 3A and 3B). VEGF expression was visible in long
patches, but not distributed throughout the whole tumor section.
These patterns of expression were not evident in the Skov-3–only
tumors (Figure 3C). The a-SMA staining is an indicator of
microvascularization within the tumor and is a contributing factor
to the TAF phenotype within the tumor microenvironment.
The fourth and final characteristic of TAF is the expression of
growth factors that support tumor development. We confirmed the
presence of HGF, EGF and IL-6 within the tumor stimulated
MSC population that we identify as TAF. The HGF and EGF
staining by IHC were present at concentrated amounts on the
leading edge of tumor where a large portion of stroma is found in
the admixed Skov-3/MSC tumors as compared to the Skov-3 only
tumors (Figure 3D and 3E). The IL-6 expression was found in
patches and at low levels in the Skov-3 only tumors. In the
admixed MSC/Skov-3 tumors, there was a widespread presence
of the IL-6 staining that was found in stronger concentrations
along the leading edges of the tumor (Figure 3F). Growth factors
stain in patches that do not correlate with the more sparse staining
patterns of the TAF markers themselves due to the fact that the
tumor cells also secrete the growth factors HGF, IL-6 and EGF in
the presence of MSC as demonstrated by in vitro co-culture data
(Figure S4).
Figure 1. In admixtures of tumor and MSC, MSC exhibit four
attributes of TAF. (A) Initially, MSC do not express all TAF markers. As
shown by western, huMSC, prior to Skov-3 tumor exposure, express low
levels of a-SMA, FAP and desmin and are negative for the expression of,
FSP, TSP-1, and Tn-C. Following 16 days exposure to Skov-3-conditioned
medium, the MSC express Tn-C, TSP-1, FSP and increase expression of
a-SMA, FAP and desmsin. (B) The TAF is a fibroblastic cell that has four
defining characteristics, which together, distinguish it from the normal
fibroblast: The fibroblastic nature of the cell (red; Fibroblast activation
protein and fibroblast specific protein); the aggressive/invasive nature
of the cell defined by the secreted proteins (green; TSP-1, Tn-C and SL1);
the vascularization potential of the cell (blue; a-SMA, desmin and VEGF);
and the growth factors secreted by the cell to aid in tumor growth and
development (yellow; EGF, HGF, IL-6 and bFGF).
doi:10.1371/journal.pone.0004992.g001
Figure 2. Admixed Skov-3/MSC xenografts express fibroblast
markers and invasive markers indicative of TAF. IHC staining for
markers that define fibroblast presence are visible in the Skov-3/MSC
(1:1) admixed xenografts but not in Skov-3-only xenografts. Fibroblast
markers FAP (A) and FSP (B) are both present throughout the admixed
tumors. The three tissue remodeling proteins Tn-C (C), TSP-1 (D) and SL-
1 (E) are detectable within the admixed tumors. These two categories
cover the first two characteristics of a TAF, and are observed only in
tumors exposed to MSC. Human-specific, mouse non-cross-reactive
antibodies allow identificationo ft h eh u m a nM S C - c o n t r i b u t o r y
components within the tumor microenvironment.
doi:10.1371/journal.pone.0004992.g002
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The size of the admixed rLuc labeled-Skov-3/huMSC and rLuc
labeled-Skov-3—only tumors was measured by bioluminescent
imaging (Figure 4A) two times per week until termination of the
experiment on day 91. Tumors consisting of Skov-3 cells only
reached an average size of 7.05610
5 p/s/cm
2 after steady growth
from day 40. However, tumors composed of Skov-3 cells and
MSC injected in a 50:50 ratio displayed a slight relative growth lag
until day 80 when rapid growth rates were observed. By day 91,
these tumors reached an average size of 1.69610
6 p/s/cm
2,
Figure 3. Admixed Skov-3/MSC xenografts express provascularization markers. One characteristic of the TAF is their ability to form
fibrovascular networks, which include vessels and the architectural foundation in which they lay. IHC staining reveals structural proteins a-SMA (A)
and desmin (B) as well as factors suggestive of tumor vascularization, including VEGF (C) in the presence of admixed MSC but not in tumors that
received no MSC (far right panel). HGF (D) is found within the stromal compartment of the tumor. A strong delineation separating the tumor and
stromal compartments is formed when the admixed xenograft is stained for HGF. Likewise, EGF (E) is highly expressed in the stromal regions of the
admixed Skov-3 tumor. (F) IL-6 staining is expressed in the Skov-3 alone tumors, however the expression is increased in the admixed tumors.
doi:10.1371/journal.pone.0004992.g003
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sacrificed due to excess tumor burden on day 91. This tumor
model typically has a 160-day lapse between tumor engraftment
and full tumor growth (data not shown). However, the addition of
50/50 Skov-3/MSC shortened the survival of the Skov-3 bearing
mice by nearly 70 days. Control mice were sacrificed for IHC
comparison to the Skov-3/MSC 50:50 tumors, but not due to
tumor burden. The mice receiving only huMSC did not develop
any tumors (Figure 4A).
Skov-3 tumor proliferation is species specific
Species specificity was confirmed by an in vitro tumor growth
assay (TGA) using admixed human ovarian Skov-3 cells and
murine MSC (muMSC) in the same 1:1 ratio used previously to
determine whether the murine cells had any significant effect on
the xenograft. The Skov-3 cells were mixed with muMSC derived
from Balb/c or C57 mice, 3T3 murine fibroblasts, or huMSC.
Cell proliferation was graphed as fold change compared to Skov-3
tumor cell proliferation alone. The murine stromal lines did not
significantly hinder the Skov-3 cell proliferation. The Balb/c MSC
reduced proliferation by a 0.75 fold difference, C57 MSC by a
0.94 fold difference and NIH-3T3 by a 1.1 fold differnence.
However, the huMSC admixed significantly increased Skov-3 cell
proliferation by 2.25 fold difference (P,0.01) after 8 days of co-
culture (Figure 4B).
MSC secreted growth factors support Skov-3 cell
proliferation
Growth factors that support tumor cell growth are secreted by
both MSC and the tumor cells when reciprocally stimulated by
one another. An initial ELISA array of several growth factors
secreted by MSC shows a significantly increased secretion
(P,0.001) of TGF-b, VEGF and IL-6 following 24 hour culture
with Skov-3 conditioned medium (CM), while HGF secretion
remains steadily expressed (Figure 4C). The reciprocal regulation
of MSC conditioning on stimulated Skov-3 tumor showed
increases in IL-6, TGF-b, VEGF and HGF secretion (Figure S4).
MSC contribution to tumor growth
Because we confirmed that enhancement of growth in our
xenograft tumor model was specific to factors produced by
huMSC and not by the mouse itself, we conducted an in vitro TGA
to determine rLuc/RFP labeled Skov-3 cell proliferation over an
8-day period under multiple co-culture conditions. Proliferation
was graphed in terms of fold change relative to Skov-3 alone.
Exposure to huMSC (P,0.01) or huMSC-conditioned medium
(P,0.01) significantly increased growth of Skov-3 cells
(Figure 5A), suggesting that growth promotion by MSC is
mediated by a paracrine effect. MSC can secrete growth factors to
support tumor cell growth. MSC co-cultured with Skov-3 cells of
Skov-3 CM secrete growth factors such as HGF, IL-6, TGF-b,
VEGF, bFGF and EGF. Each of these factors were added
individually as recombinant proteins to the Skov-3 cell TGA
culture. The HGF, bFGF, TGF-b and VEGF had minimal impact
on Skov-3 proliferation, while added EGF (P,0.05) and IL-6
significantly (P,0.01) enhanced Skov-3 growth rates (Figure 5A).
Skov-3 tumor proliferation was measured based on fold change
compared to normal Skov-3 cell proliferation in low serum media
as detailed in the methods section.
To confirm the importance of huMSC-secreted EGF and IL-6
on Skov-3 cell proliferation, we co-cultured huMSC and rLuc/
RFP labeled Skov-3 in vitro and immunoprecipitated (IP) EGF
and/or IL-6 out of solution (individually and in combination). IP
of IL-6 from the MSC-CM showed significantly decreased Skov-3
proliferation (P,0.01; Figure 5B). IP of EGF from the MSC-CM
was not significant and showed similar Skov-3 proliferation to that
of the isotype controls. While several growth factors may be
necessary for the in vivo progression of the Skov-3 tumor, in vitro
studies revealed huMSC-induced IL-6 secretion to be critical for
the enhanced proliferation observed in Skov-3/MSC TGA.
Figure 4. huMSC secreted growth factors promote growth of
Skov-3 tumors. The TAF phenotype includes secretion of pro-
tumorigenic growth factors. (A) Supported by the secretion of growth
factors by the huMSC. In vivo growth of xenograft Skov-3 tumors
steadily progress but when mixed at a 1:1 ratio with MSC rapid growth
ensued after day 65. At day 91, the Skov-3/MSC 50/50 tumors were
significantly larger than the Skov-3 alone (P,0.05). (B) Skov-3 tumor cell
growth is species dependent. The Skov-3 ovarian tumor cells were
growth in co-culture with huMSC, and several muMSC including cells
isolated from balb/c and C57 mice, and a fibroblast cell line, 3T3.
Growth is graphed as fold change relative to normal Skov-3
proliferation. The only cell line that produced adequate factors to
induce cell growth is the huMSC (red circles). The huMSC induced Skov-
3 growth significantly (P,0.01) better than the other cell lines. (C) Naı ¨ve
MSC produce basal levels of IL-6, TGF-b, VEGF and HGF. All secreted
factors with the exception of HGF are significantly increased upon
stimulation with Skov-3 CM (P,0.001).
doi:10.1371/journal.pone.0004992.g004
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Tumor stroma, fibrovascular networks and the tumor micro-
environment are vital to the structural integrity of the tumor and
its preservation/proliferation. TAF cells are derived from cells of
two different origins, most likely a combination of both. The first is
the bone marrow-derived progenitor population of which both
hematopoietic stem cells [6] and MSC [12,21,22] are suggested as
precursors; the second is a tissue-resident MSC population. MSC
are not only a bone marrow resident population of cells, but they
are also a tissue resident population and may even be a circulating
population. In our experiments we set out to show that MSC, in
toto, is the precursor to the tumor associated fibroblast (TAF).
TAF are defined as an activated fibroblast population, which is
a rich source of growth factors, such as HGF and TGFb [10].
Activated fibroblasts form fibrovascular stromal patterns, a diverse
arrangement of septa within tumors; their presence represents
disordered, rapid tumor growth and can be associated with
heightened tumor aggressiveness and poor prognostic outcome
[23]. We show the ‘‘activation’’ of MSC by tumor conditioned
media by the increase of TAF-like surface markers (Figure 1A).
Activated fibroblasts and myofibroblasts contribute to the
formation of microvascular structures and can be detected by a-
SMA and desmin expression [24,25]. Recently, published data
identify pericyte characteristics by a-SMA staining within an in vivo
glioma tumor model of systemically injected MSC [26]. MSC are
pericytic precursors [27], and thus we hypothesize that they are
precursors of TAF, which are identified by pericytic, myofibro-
blastic and ‘‘activated’’ fibroblastic markers. These TAF arise from
the admixed MSC population to promote growth, matrix
remodeling, and neovascularization of xenograft tumors.
MSC represent a relatively well-defined ex vivo cell population
with complex and poorly understood biology in vivo [28,29]. MSC-
based anticancer therapies represent an exciting and novel
therapeutic approach, but a better understanding of how MSC
home to, engraft within and ultimately have an impact on tumor
behavior will be essential before we can realize the full potential
including the risks of using of MSC-based delivery systems in a
clinical setting. The first indication that MSC had a natural affinity
for tumors was reported by our group in 2001 [30]. In those and
subsequent studies, we demonstrated that MSC, administered
intravenously, were able to integrate and persist within tumor
stroma of pre-established human melanoma, breast cancer and
glioma xenografts [11,12,16]. These data were confirmed in other
tumor models [31,32], most recently by Weinberg et al. [33]. We
also demonstrated that MSC could deliver therapeutic doses of
interferon-beta, locally within a tumor, and demonstrated that this
treatment had significant anti-tumor effects [11,12,16]. The use of
cell-based delivery systems such as MSC holds clinical promise
and significant current research effort is focused in this area. We
provide evidence herein, that the MSC has the potential to be
tumor supportive. This should not dissuade the pursuit of MSC as
gene delivery vehicles, but instead, serve as a caveat in the
preemptive strike against potential pitfalls in the future of targeted
gene delivery.
In these experiments, we show enhanced tumor growth is the
effect of a 1:1 ratio of tumor:MSC in vivo. However, in previous
studies with altered tumor:MSC ratios, MSC have had adverse
effects on tumor growth, prolonging the survival of the mice by
hampering tumor proliferation (data not shown) [34–37]. In
contrast to MSC inhibiting tumor progression and similar to what
is described within this paper, our previous data shows that MSC
can enhance the growth rate of a subpopulation of breast cancer
cells in vitro and in vivo through paracrine interleukin-6 (IL-6)
signaling events [38,39].
Through IHC, we initially observed the formation of a
fibrovascular structure and ‘‘TAF characteristics’’ by systemically
circulating MSC engrafting within established xenograft tumor
models. Figure S3 shows the expression of the TAF markers: a-
SMA, desmin, Tn-C and TSP-1 in ovarian, breast and pancreatic
tumor models. Each of these tumor models received injections of
MSC, yet after 14 weeks, the participation of the MSC in the
tumors resulted in the expression of the same TAF markers
observed in the admixed Skov-3/MSC tumor model. Interesting-
ly, although each tumor type utilized the MSC as a TAF, as
confirmed by the presence of a-SMA, desmin, Tn-C and TSP1,
similarities between the IHC staining patterns do not exist across
tumor types. Potentially due to the heterogeneity in paracrine
factor expression between breast, ovarian and pancreatic tumor
types, each tumor appears to elicit different responses or
requirements from MSC, however, the presence of the TAF-
markers is a unifying factor between the all three tumors.
Subsequently, an admixed xenograft experiment of Skov-3
ovarian tumor cells and huMSC was used to further demonstrate
the formation of fibrovascular networks in the admixed Skov-3/
MSC tumors and not in the Skov-3-only tumors, indicating that
MSC give rise to TAF within the tumor microenvironment. First,
the four defining characteristics illustrated in Figure 1 are sought
by IHC staining of 91-day-old admixed Skov-3/MSC xenograft
tumors. We indicate the neovascular, fibroblastic, pericytic, and
Figure 5. Growth factors are critical to Skov-3 tumor progres-
sion. (A) An in vitro 3D tumor growth assay (TGA) at day 8. Briefly, RFP-
labeled Skov-3 tumor cells were mixed with huMSC cells, huMSC
conditioned media (CM) or various recombinant cytokines (FGF, HGF,
TGF-b, VEGF, EGF, IL-6) in a 3D assays (as described in the materials and
methods). EGF (P,0.05) and IL6 (P,0.01) significantly increased the
proliferation of Skov-3 cells compared to the Skov-3 only, but less than
the MSC (P,0.01) induced Skov-3 proliferation. (B) Immunoprecipita-
tion of IL-6 from the Skov-3/MSC co-culture medium over an 8 day
period reveals significantly reduced growth of the Skov-3 (P,0.01) cells
as compared with the Skov-3/MSCco-culture. Cell growth is graphed as
fold change relative to normal Skov-3 proliferation.
doi:10.1371/journal.pone.0004992.g005
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contribution of the TAF to the leading edge stromal component of
the tumor microenvironment.
The first characteristic requires expression of two fibroblastic
markers: FAP, which is expressed on MSC and fibroblasts [40]
and FSP, a marker overexpressed in TAF as compared to normal
fibroblasts [41]. The expression of both markers is evident in both
the systemic-MSC injected model and the admixed MSC model
and furthermore not evident in the Skov-3-only IHC staining
(Figure 2A and 2B, Figure S3).
The second characteristic is the degree of expression of the
proteins of ‘‘aggression’’ such as SL-1, otherwise known as MMP-
3, a degradative enzyme highly expressed by fibroblasts [42] and
utilized in tissue remodeling by TAF [21]. Positive staining for SL-
1 was identified in Skov-3/MSC admixed tumors but Skov-3
alone as were other pathogenic-associated glycoproteins Tn-C and
Tsp-1 (Figure 2C, 2D, and 2E).
The third characteristic is the expression of typical myofibro-
blast-associated proteins. Desmin, a muscle-specific, intermediate
filament protein common in myofibrils [43], was expressed in
huMSC derived fibroblasts in a heterogeneous pattern of
distribution. The expression patterns of desmin are comparable
to the global expression pattern observed on staining for a-SMA of
admixed Skov-3/MSC tumors (Figure 3A and 3B). a-SMA
positivity has been used previously to identify differentiated MSC
[44]. Our data suggests that MSC do contribute to the
perivascular formation within the admixed Skov-3 tumors because
much of the human specific a-SMA and desmin positive staining is
evident around tumor vessel structures.
Typically, the cells associated with the abnormal, tumor-
associated, fibrovascular septa are not the archetypal vascular
endothelial cells classified by factor VIII, CD31 and CD34, but
instead are networks consisting of collagen and laminin subtypes in
addition to activated fibroblasts and macrophages [45]. Initial
gene-expression profiles of long-term Skov-3—conditioned MSC
reveal the upregulation of several laminin and collagen subtypes
(data not shown); the deposition of these matrix proteins is
associated with pre-vasculogenesis in preparation for the later
stages including angiogenesis [46]. The TAF potential to support
microvascular sprouting corroborates the in vivo tumor growth
advantage of the admixed Skov-3/MSC tumors (Figure 4A). The
microvascular formation that we elude to is restricted in vivo tumor
growth (depicted in cartoon fashion in Figure S2) and is
characterized by networks of straight, looping and branching
arced speta seen in both the a-SMA and desmin stained slides
(Figure 3A and 3B). Abnormal septa formation is indicative of
vascular support due to the presence of the MSC (TAF) within the
tumor microenvironment and is otherwise not observed. Micro-
vascular channel formation is specific to tumor vasculogenesis and
is featured by the small, un-orderly arrangement of microvessels
that we depict through a-SMA, desmin and VEGF staining
(Figure 3).
The fourth and final characteristic that defines a TAF is
secretion of tumor-supportive growth factors, including HGF,
EGF and IL6 (Figure 3D, 3E, and 3F). The growth factors
secreted by the MSC are known to induce a TAF-like phenotype,
thus providing autocrine stimulation to the MSC itself to
differentiate into a TAF. Skov-3 cells and MSC interact in a
paracrine manner by inducing reciprocal growth factor expression
including IL-6, VEGF, HGF and TGF-b (Figure 4C and
Figure S4). TGF-b induces HGF expression by fibroblasts [47]
but also induces the transition of fibroblasts to myofibroblasts by
increasing a-SMA and Tn-C expression [48]. Several adenocar-
cinoma tumor-microenvironment crosstalk models implicate
growth factors including HGF, [49] VEGF, [50] TGF-b, and
FGF [51] in the promotion/progression of tumorigenesis. The
HGF/c-Met interaction plays a pivotal role in cancer invasion that
is mediated by the tumor stromal cell production of HGF [52],
which can induce ECM degradation, tubule formation and
angiogenesis [53]. HGF also has the ability to transactivate the
EGF receptor to induce motility [54] and reciprocally, EGF is able
to stimulate HGF production [52].
In our in vitro studies, both MSC and Skov-3 cells showed
reciprocal induction of growth factors (IL-6, TGF-b1, VEGF and
HGF) following 24 hours conditioning (Figure 4C and Figure
S4). Only EGF and IL-6 and not FGF, HGF, TGF-b1 or VEGF
proved to be essential components of the growth advantage
observed for the mixed labeled Skov-3 TGA cultures in
comparison with the labeled-Skov-3-only cultures for the first 8
days of co-culture. The in vitro presence of MSC, MSC-
conditioned medium EGF and IL-6 is essential to the growth of
tumor cells in a controlled Matrigel environment without the
presence of MSC (Figure 5A). Furthermore, MSC-conditioned
medium stripped of IL-6 induced the same growth rates observed
in the Skov-3 tumor cells alone (Figure 5B). While recombinant
EGF enhanced Skov-3 proliferation (Figure 5A), the immuno-
precipitation of EGF from MSC conditioned medium did not
significantly effect Skov-3 tumor growth. MSC-secreted EGF, in
vitro, is not sufficient to enhance Skov-3 proliferation as seen with
MSC-secreted IL-6. On the basis of our in vitro tumor growth assay
data, we conclude that the MSC produced paracrine factors HGF,
FGF, TGF-b, VEGF and EGF do not individually affect the
growth rate of the Skov-3 xenograft, whereas IL-6 does enhance
the proliferation as confirmed by the IP of IL-6 out of MSC
conditioned medium (Figure 5B).
The discrepancy between the in vivo and in vitro data is
significant, however, the in vitro data measured the first 8 days of
tumor cell proliferation, whereas the in vivo data revealed day 91 of
tumor proliferation. Accordingly, we suggest that several growth
factors mediate the transition from the tumor supportive MSC to
the tumor supportive TAF. In vitro, only IL-6 is significant to the
initial ovarian cell line proliferation. While none of the other
factors showed significant effects on tumor cell proliferation
individually, the significance and contribution of these factors
observed in the xenograft model should not be overlooked. The
presence of HGF and EGF in vivo (Figure 3D and 3E), may have
an impact on growth later phase growth (past day 8) or likewise in
other tumor models.
Like estrogen receptor alpha (ERa)—positive breast cancer
cells, on which we have previously reported [38,39], our MSC-
enhanced Skov-3 growth relies on MSC-secreted paracrine
factors, such as IL-6, and not strictly on cell-cell contact. Unlike
MSC-supported ERa-positive breast cancer cells, however, Skov-3
ovarian cancer cell growth is enhanced by IL-6. This exemplifies
the diversity of the MSC as a functionally supportive cell in
multiple environments. We showed here that MSC secreted IL-6 is
key to the growth of the Skov-3 ovarian tumor model while we
showed previously the importance of MSC-secreted EGF to the
ERa-positive breast cancer model. MSC are able to respond to
distinctive stimuli from individual microenvironments to elicit the
proper function that environment.
In conclusion, the MSC play an integral role in the
development of the mature, complex, physiological tumor
microenvironment. This study represents an early step in better
defining the biological activities of MSC within said environment.
Our finding that MSC secreted paracrine factor, IL-6, enhances
early stage Skov-3 proliferation emphasizes the importance of a
proper microenvironment for tumor growth. Furthermore, we
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tumor microenvironment, as it contributed to fibrovascular
formation within that microenvironment that were not evident
in Skov-3 only tumors. The tumor microenvironment within a
xenograft mouse model occupied by MSC becomes a much more
intricate environment, mimicking the complex physiological tumor
microenvironment in humans. Reiteration of the diverse pheno-
type of the TAF is necessary; TAF can be matrix-synthesizing or
matrix-degrading cells, they can be contractile cells (myofibro-
blasts), circulating precursor cells (fibrocytes), or blood vessel-
associated pericytes [10,21]. Nonetheless, TAF, in whichever form
they represent in the tumor microenvironment, biologically impact
tumor progression through the production of growth factors,
cytokines, chemokines, matrix-degrading enzymes, and immuno-
modulatory mechanisms.
Materials and Methods
Cell isolation and culture
Normal huMSC were provided through the Tulane Center for
Gene Therapy, MSC cell distribution center (Darwin Prockop,
Tulane University, New Orleans, LA). Tulane Center for Gene
Therapy provides well-characterized human mesenchymal stem
cells. These adult stem cells are the plastic adherent fraction from
bone marrow. The cells are isolated, expanded and extensively
characterized (see URL link for characteristics of the cells,
including phenotypic analysis, proliferation rate, expansion data,
colony forming units, and trilineage differentiation into mineral-
izing cells, adipocytes and chondrocytes: http://www.som.tulane.
edu/gene_therapy/distribute_docs/Spec_Sheet.pdf). These cells
were thawed, and expanded in alpha-minimum essential medium
(MEM; Mediatech, Herndon, VA) 20% fetal bovine serum (FBS;
Invitrogen, Carlsbad, CA) at 37uC. After 1 passage cells were split
and a fraction of the cells were phenotypically analyzed to ensure
the quality of the cells. MSC were expanded passage number 1–4
were used in the subsequent experiments.
Human ovarian cancer Skov-3, breast cancer MDA-231 and
pancreatic cancer Panc-1 cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA) and cultured in
minimum essential medium/Earl’s salts non-essential amino acid
medium supplemented with 10% FBS, L-glutamine and the
penicillin-streptomycin mixture (Invitrogen, Carlsbad, CA). Mu-
rine MSC (mMSC) cell lines from C57/B6, balb/C were isolated
as described previously [55] Fibroblast 3T3 cells and mMSC were
cultured in alpha-MEM containing 20% FBS and 10% LPS.
Skov-3 tumor cells were stably transduced using a lentivirus
expressing red fluorescent protein and renilla luciferase (rLuc)
[56,57].
Animals
Female CB-17 SCID mice were purchased from Harlan
(Indianapolis, IN). Mice were housed and used in accordance
with institutional guidelines of the University of Texas, M.D
Anderson Cancer Center under IACUC approved protocols (FC
Marini). The UTMDACC’s animal care and use program has
been fully accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care International (AAA-
LAC).
Xenograft mouse models
Admixed MSC/Skov-3. The admixture (co-injection)
studies were carried out with 4610
6 cells comprising Skov-3
and huMSC cells in the following ratios: huMSC alone (n=5),
Skov-3 alone (n=5), or 50:50 mixture (n=5). All injections were
given to anesthetized animals; tumor cells were suspended in
200 ml PBS and administered via subcutaneous administration to
the shaven rear flank. Mice were observed and tumor growth was
measure by both bioluminescent imaging (Xenogen IVIS
bioluminescence/fluorescence optical imaging system; Caliper
Life Sciences, Hopkinton, MA) until day 91 when mice were
euthanized due to excess tumor burden. Tumors were removed
and stored in OTC compound (Miles, Inc., Elkhart, IN) and then
snap-frozen in liquid nitrogen and stored at 280uC until tissue
processing.
Systemic MSC Injection. Mice received an intraperitoneal
injection of 4610
6 Skov-3 cells suspended in 1 ml PBS on day
zero. MDA-231-only and Panc-1-only xenograft mice received a
subcutaneous injection of 1610
6 cells in the mammary fat pad or
lateral flank, respectively. Survival was measured from the day of
tumor cell injection until the day of death. Tumor engraftment
was evident by palpable tumor after 12 days. For each of the
experiments, fifteen of these mice received four weekly injections,
2 weeks post tumor engraftment, of 1610
6 huMSC alone (1 ml
PBS suspension ip for the Skov-3 model or 100 ml PBS suspension
iv for the breast and pancreatic models); a control group (n=4)
received no huMSC. Mice were euthanized on week 14. Tumor
growth was measured biweekly using bioluminescent imaging
(IVIS-Xenogen 200; Caliper Lifesciences, Hopkinton, MA) end-
point tumor size was measured with a caliper as well as in vivo
imaging. Tumors were removed and stored in OTC compound
(Miles, Inc., Elkhart, IN) and then snap-frozen in liquid nitrogen
and stored at 280uC until tissue processing.
Tissue processing
On day 91, all mice were sacrificed and tumor tissues were
removed and embedded in OTC compound (Miles, Inc., Elkhart,
IN), snap-frozen in liquid nitrogen and stored at 280uC. Frozen
tissue was sectioned (6–8 mm) and processed for hematoxylin-eosin
or IHC staining. Sections were imaged with a Zeiss Axioplan2
microscope (Carl Zeiss Inc, Thornwood, NY) equipped with a
charge-coupled device (CCD) camera (Hamamatsu Co., Bridge-
water, NJ) and Adobe Photoshop software (Adobe Systems Inc.,
San Jose, CA).
Imaging studies
Tumor growth was followed through noninvasive in vivo optical
imaging (Xenogen IVIS bioluminescence/fluorescence optical
imaging system; Caliper Life Sciences, Hopkinton, MA) biweekly
for 91 days. Five minutes prior to imaging, each mouse was given
an IP injection of a 100 ml injection of 40 mg/ml coelenterazine
as described previously [56]. General anesthesia was then
induced with 5% isoflurane (IsoSol, Medeva Pharmaceutical
PA, Inc.); the mouse was placed in the light-tight heated chamber
during which anesthesia was continued with 2% isoflurane
introduced via nose cone. The imaging system consists of a
cooled, back-thinned CCD camera to capture both a visible light
photograph of the animal taken with light-emitting diodes and
the luminescent image. Luminescent images were acquired with
1- to 3-minute exposure times. Optical images were displayed
and analyzed with IVIS Living Image (Caliper Life Sciences
[Xenogen], Hopkinton, MA) software packages. Regions of
interest were manually drawn around the bodies of the mice to
assess signal intensity emitted. Optical signal was expressed as
photon flux, in units of photons/second/centimeter
2 (p/s/cm
2).
Tumor growth is translated into photon flux as a unit of
measurement directly proportional to the number of rLuc-
expressing tumor cells.
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All antibodies were human specific and were exhaustively tested
against multiple mouse tissues to confirm the species specificity
and non–cross-reactivity between species. huMSC differentiation
in vivo was examined in frozen sections of mouse tumor xenografts
on day 91 of tumor growth when animals were sacrificed.
Adjacent tumor sections were only used to show MSC co-
localization with a-SMA; all other sections presented are not
directly adjacent to one another. Sections were fixed for 5 minutes
in neutral buffered formalin, after which endogenous peroxidase
activity was quenched by incubating the sections in 0.3%
hydrogen peroxide in methanol for 30 minutes. The sections were
treated with the following antibodies: rabbit anti-human FSP,
mouse anti-human FAP and mouse anti-human Tn-C (1:1000
dilution; Abcam, Cambridge, MA), goat anti-human HGF (1:1000
dilution; R&D Systems, Minneapolis, MN) and mouse anti-human
thrombospondin (1:1000 dilution; Lifespan Biosciences; Seattle,
WA), mouse anti-human a-SMA (1:1000 dilution; Biomeda,
Foster City, CA), rabbit anti-human desmin (diluted 1:1000;
Novus Biologicals, Littleton, CO), mouse anti-human Thy 1
(BioLegend, SanDiego, CA), mouse-anti-human SL-1, mouse anti-
human VEGF, mouse anti-human EGF, (1:1000 dilution; Santa
Cruz Biotechnology Inc, Santa Cruz, CA), mouse antistromal
antigen (1:1000 dilution; Dianova, Hamburg, Germany), rat anti-
human IL-6 (1:200; Abcam, Cambridge, MA) and mouse anti-
human TGF-bIIR (1:1000; DakoCytomation, Carpinteria, CA).
We followed the manufacturer’s procedures for the goat, rabbit or
mouse peroxidase kits (Vector Laboratories, Burlingame, CA).
Peroxidase substrate was developed by using the AEC (3-amino-9-
ethylcarbazole) and/or DAB (3,39-diaminobenzidine) substrate kit
(Vector Laboratories). Slides were counterstained with hematox-
ylin QS (Vector Laboratories) and were either mounted with low-
viscosity aqueous mounting medium (Scytek Laboratories, Logan,
UT) or dehydrated and mounted with VectaMount Permanent
Mounting Medium (Vector Laboratories).
In vitro tumor conditioning
MSC were grown to 40% confluency in a-MEM supplemented
with 20% FBS and 10% PSG in T-175 flasks. Skov-3 cells were
cultured to 50% confluency before they were switched to a serum
free growth medium. After 2 days, the Skov-3 medium was
removed, filtered (0.2 mm filter) and placed on the MSC. MSC
were conditioned for 24 hours prior to ELISA analysis of TGF-b,
IL-6, VEGF and HGF. Reciprocal 24 hour conditioning was
carried out for the MSC conditioned Skov-3 tumor cells prior to
ELISA measurements of TGF-b, VEGF, HGF and IL-6. The long
term conditioned MSC were conditioned with Skov-3-conditioned
medium for 16 days. Media was changed every 3 days and MSC
were maintained between 40% and 80% confluency. Cells were
then analyzed by western blot for the presence of TAF-like protein
expression. Controls cells for ELISA and western blot were
conditioned in serum free a-MEM.
Western blot
MSC, fibroblasts, and Skov-3 cells were grown and conditioned
on 10cm tissue culture dishes. When cells were 50% confluent,
they were serum starved overnight before 16 day-conditioning.
Cells were maintained at a cell density of 4000 cells/cm
2. After 16
days, cells were washed 26 with PBS, scraped in PBS and spun
down at 300 rpm for 5 minutes before the addition of 50 mLo f
phosphoprotein (NP40) lysis buffer (25 mm HEPES, 150 mm
NaCl, 1 mm EDTA, 25 mm NaF, 5% glycerol, 1 mm Na-
orthovandate, 1% NP40, 0.5% Triton x-100, 1.4 mg/ml aproti-
nin, 100mm PMSF, 250 mg/mL benzamindine and 1.25 M
b-glycerol phosphate). Lysates were separated on a 12%
polyacrylamide gel, transferred to Hybond-P membranes (Amer-
sham Pharmacia Biotech, Buckinghamshire, England) and probed
with primary antibodies. Cell lysates were added at 20 mg per well
and run for 90 minutes at 100 volts. Transfers were performed for
2.5 hours at 400 mA. Antibodies used for western include, FAP
(1:200 dilution; Abcam, Cambridge, MA), FSP (1:200 dilution;
Lifespan Biosciences; Seattle, WA), desmin (1:200 dilution;
Abcam, Cambridge, MA), Tsp-1 (1:400 dilution; Lifespan
Biosciences; Seattle, WA), a-SMA (1:200 dilution; Abcam, Cam-
bridge, MA), Tn-C (1:200 dilution; Abcam, Cambridge, MA),
tubulin (1:2000 dilution; Cell Signaling), secondary anti-mouse
and anti-rabbit antibodies (1:1000 dilution; Cell Signalling) Bands
were visualized using an enhanced chemiluminescence plus kit
(Amersham Pharmacia Biotech).
Flow cytometry
MSC that reached 80% confluency were trypsinized and
washed three times with PBS, then 1610
5 cells were resuspended
in 1 mg/ml of primary antibody or conjugated antibody for
15 minutes on ice. Cells were then washed two times in PBS and
resuspended in a 1:25 dilution of anti-mouse-phycoerythrin (PE)-
secondary antibody for 15 minutes on ice. Cells were washed two
times in PBS and resuspended in 250 ml PBS on ice until analyzed
on an LSRII flow cytometer (BD Biosciences, San Jose, CA).
Unconjugated antibodies used included desmin, a-SMA, Tn-C,
FAP, FSP (Abcam, Cambridge, MA) with anti-mouse or anti-
rabbit PE secondary (Abcam, Cambridge, MA), Conjugated
antibodies utilized included PE-conjugated CD105, CD90,
CD73, CD44, CD31, CD34 and CD45 (BD Biosciences, San
Jose, CA).
Tumor growth assay (3D TGA)
In vitro tumor cell proliferation is detected by the fluorescence-
based 3D TGA that noninvasively monitors tumor cell growth for
eight days after cells are embedded in Cultrex BME at 3 mg/mL
[38,39]. Briefly, red fluorescent (rLUC/RFP-labeled) Skov-3
tumor cells were embedded (in triplicate) in a 100 mL plug of
3 mg/mL Cultrex BME in a black-walled, clear-bottom 96-well
plate at 12,500 tumor cells (6) 3D MSC-CM, 3D MSC-CM(-GF)
(i.e., 3D MSC-CM with one of several growth factor (GF) listed
below removed via immunoprecipitation), or recombinant GF as
indicated. Wells were overlaid with phenol red–free, serum-free
RPMI 1640. Individual well fluorescence intensities were moni-
tored daily for eight days. Relative Skov-3 growth rates were
documented as relative fluorescence units and graphed as fold
change (growth). An all inclusive description of this assay and its
utility for evaluating growth rate kinetics of breast cancer cells in
complex 3D tumor-like microenvironments can be found in our
previously published studies [38,39].
Soluble protein quantification. MSC-CM was assayed for
IL-6, EGF, HGF, VEGF, TGF-b1 and FGF protein levels using
the respective DuoSet Human ELISA (R&D Systems). The ELISA
was performed according to the manufacturer’s instructions. In
addition, each growth factor was removed from a subset of MSC-
CM from 3D/Cultrex BME by GF immunoprecipitation (see
below).
GF immunoprecipitation. GF (IL-6, EGF, HGF, VEGF,
TGF-b1 and FGF) was immunoprecipitated as previously
described [39]. The 3D MSC-CM was incubated with 2 mg/mL
anti-GF monoclonal antibody (Mab206, Mab636, Mab294,
Mab293, Mab1835 and AF233NA; R&D Systems) for 4 to 6 h
at 4uC with constant rotation. To verify that each GF had been
removed from the conditioned medium, an aliquot of conditioned
MSC Become TAF in Tumor
PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e4992medium stripped of GF via immunoprecipitation was tested for the
respective GF concentration by ELISA, and in all cases, GF
concentrations were .14-fold less as determined by ELISA.
Supporting Information
Figure S1 MSC characterization. MSC were sorted by flow and
were positive for CD105, CD90, CD44, CD73, and CD140b, and
negative for the endothelial cell marker and hematopoietic
markers CD31, CD34, and CD45.
Found at: doi:10.1371/journal.pone.0004992.s001 (0.21 MB TIF)
Figure S2 Archetypical stromal patterns found in tumors. The
microvascular patterns often found in tumor masses include
enlarged vessel walls and septa that are not uniform, but are often
arched or branched or looped in pattern, thus creating an
unorganized support structure and inefficient vascularization
throughout the tumor. The cartoon depiction shows the
microvascular structure as stained by a-SMA.
Found at: doi:10.1371/journal.pone.0004992.s002 (5.26 MB TIF)
Figure S3 In ovarian, breast, and pancreatic xenograft mouse
models, tumors show patterns of fibrovascular networks following
intravenous injection of huMSC. Tumor cells, were allowed to
engraft prior to administration of huMSC [4 times, once per week,
Skov-3 (IP), MDA-231 (IV) or Panc-1 (IV)]. On week 14, mice
were sacrificed and tumors for histology were collected. (A) We
stained for the presence of MSC (Thy-1) which we showed co-
localized expression with a-SMA on adjacent tissue sections. (B)
Further tissue sections are not adjacent sections. All three tumor
types show fibrovascular network pattern staining of a-SMA, (C)
desmin, (D) Tn-C, and (E) TSP-1 within the tumors that were
treated with MSC while tumors not treated with MSC showed no
staining (negative tumor, Skov-3-only, is representative of MDA
and Panc-1 tumors).
Found at: doi:10.1371/journal.pone.0004992.s003 (6.51 MB
PDF)
Figure S4 Skov-3 tumor cell secretion of growth factors
following the stimulation with MSC-CM. Secreted proteins are
measured from Skov-3 tumor cell cultures prior to and post
stimulation with MSC-CM. IL-6 (P,0.0001), VEGF (P,0.01),
HGF (P,0.0001) and TGF-b (P,0.001) secretion are all
increased following conditioning with MSC CM.
Found at: doi:10.1371/journal.pone.0004992.s004 (0.34 MB TIF)
Author Contributions
Conceived and designed the experiments: FM. Performed the experiments:
ELS JLD KS KW BH. Analyzed the data: ELS JLD FM. Contributed
reagents/materials/analysis tools: MA. Wrote the paper: ELS JLD AK
FM.
References
1. Wels J, Kaplan RN, Rafii S, Lyden D (2008) Migratory neighbors and distant
invaders: Tumor-associated niche cells. Genes Dev 22: 559–574.
2. Udagawa T, Puder M, Wood M, Schaefer BC, D’Amato RJ (2006) Analysis of
tumor-associated stromal cells using SCID GFP transgenic mice: contribution of
local and bone marrow-derived host cells. FASEB J 20: 95–102.
3. Koyama H, Kobayashi N, Harada M, Takeoka M, Kawai Y, et al. (2008)
Significance of tumor-associated stroma in promotion of intratumoral lymphan-
giogenesis: pivotal role of a hyaluronan-rich tumor microenvironment.
Am J Pathol 172: 179–193.
4. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, et al. (2004) VEGF-null cells
require PDGFR alpha signaling-mediated stromal fibroblast recruitment for
tumorigenesis. EMBO J 23: 2800–2810.
5. Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, et al. (2005) The
contribution of bone marrow-derived cells to the tumor vasculature in
neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res 65:
3200–3208.
6. Ogawa M, LaRue AC, Drake CJ (2006) Hematopoietic origin of fibroblasts/
myofibroblasts: Its pathophysiologic implications. Blood 108: 2893–2896.
7. Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, et al. (2007) Stromal
myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res
13: 2082–2090.
8. Yazhou C, Wenlv S, Weidong Z, Licun W (2004) Clinicopathological
significance of stromal myofibroblasts in invasive ductal carcinoma of the
breast. Tumour Biol 25: 290–295.
9. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA (2004) The fibroblast:
sentinel cell and local immune modulator in tumor tissue. Int J Cancer 108:
173–180.
10. Kunz-Schughart LA, Knuechel R (2002) Tumor-associated fibroblasts (part I):
Active stromal participants in tumor development and progression? Histol
Histopathol 17: 599–621.
11. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, et al. (2002) Bone
marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery
into tumors. Cancer Res 62: 3603–3608.
12. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, et al.
(2004) Mesenchymal stem cells: potential precursors for tumor stroma and
targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:
1593–1603.
13. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F (2008) Inflammation
and tumor microenvironments: defining the migratory itinerary of mesenchymal
stem cells. Gene Ther.
14. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor
stroma generation and wound healing. N Engl J Med 315: 1650–1659.
15. Haddow A (1972) Molecular repair, wound healing, and carcinogenesis: tumor
production a possible overhealing? Adv Cancer Res 16: 181–234.
16. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, et al. (2005) Human
bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Cancer Res 65: 3307–3318.
17. Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, et al. (2007)
Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived
mesenchymal stem cells. Cancer Gene Ther 14: 894–903.
18. Xin H, Kanehira M, Mizuguchi H, Hayakawa T, Kikuchi T, et al. (2007)
Targeted-Delivery of CX3CL1 to Multiple Lung Tumors by Mesenchymal
Stem Cells. Stem Cells.
19. Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, et al. (2008)
Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to
Intracranial Glioma. Stem Cells.
20. Emura M, Ochiai A, Horino M, Arndt W, Kamino K, et al. (2000)
Development of myofibroblasts from human bone marrow mesenchymal stem
cells cocultured with human colon carcinoma cells and TGF beta 1 [3]. In Vitro
Cell Dev Biol Anim 36: 77–80.
21. Hall B, Andreeff M, Marini F (2007) The participation of mesenchymal stem
cells in tumor stroma formation and their application as targeted-gene delivery
vehicles. Handb Exp Pharmacol (180): 263–283.
22. Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, et al. (2007)
Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based
delivery vehicles. Int J Hematol 86: 8–16.
23. Ruiter D, Bogenrieder T, Elder D, Herlyn M (2002) Melanoma-stroma
interactions: Structural and functional aspects. Lancet Oncol 3: 35–43.
24. Ball SG, Shuttleworth AC, Kielty CM (2004) Direct cell contact influences bone
marrow mesenchymal stem cell fate. Int J Biochem Cell Biol 36: 714–727.
25. Kinner B, Zaleskas JM, Spector M (2002) Regulation of smooth muscle actin
expression and contraction in adult human mesenchymal stem cells. Exp Cell
Res 278: 72–83.
26. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, et al. (2008) Bone
Marrow Multipotent Mesenchymal Stroma Cells Act as Pericyte-like Migratory
Vehicles in Experimental Gliomas. Mol Ther.
27. Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, et al. (2008) Cancer-derived
lysophosphatidic acid stimulates differentiation of human mesenchymal stem
cells to myofibroblast-like cells. Stem Cells 26: 789–797.
28. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, et al.
(2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement. Cytotherapy 8:
315–317.
29. Javazon EH, Beggs KJ, Flake AW (2004) Mesenchymal stem cells: Paradoxes of
passaging. Exp Hematol 32: 414–425.
30. Studeny M, Marini FC, Zompetta C, Champlin RE, Filder IJ, et al. (2001) Bone
marrow derived mesenchymal stem cells serve as precursors for stromal
fibroblasts in malignant tumors and show potential for cancer therapy. Blood 98.
31. Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, et al. (2005) Mesenchymal
stem cell targeting of microscopic tumors and tumor stroma development
monitored by noninvasive in vivo positron emission tomography imaging. Clin
Cancer Res 11: 7749–7756.
32. Annabi B, Naud E, Lee Y-, Eliopoulos N, Galipeau J (2004) Vascular
progenitors derived from murine bone marrow stromal cells are regulated by
MSC Become TAF in Tumor
PLoS ONE | www.plosone.org 10 April 2009 | Volume 4 | Issue 4 | e4992fibroblast growth factor and are avidly recruited by vascularizing tumors. J Cell
Biochem 91: 1146–1158.
33. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007)
Mesenchymal stem cells within tumour stroma promote breast cancer
metastasis. Nature 449: 557–563.
34. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, et al. (2004)
Antitumor effect of genetically engineered mesenchymal stem cells in a rat
glioma model. Gene Ther 11: 1155–1164.
35. Jiang H, Ren J (2008) Inoculation of murine bone marrow mesenchymal stem
cells induces tumor necrosis in mouse with orthotopic hepatocellular carcinoma.
Beijing Da Xue Xue Bao 40: 453–458.
36. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, et al. (2006) Human
mesenchymal stem cells exert potent antitumorigenic effects in a model of
Kaposi’s sarcoma. J Exp Med 203: 1235–1247.
37. Ohlsson LB, Varas L, Kjellman C, Edvardsen K, Lindvall M (2003)
Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and
in vitro in gelatin matrix. Exp Mol Pathol 75: 248–255.
38. Sasser AK, Mundy BL, Smith KM, Studebaker AW, Axel AE, et al. (2007)
Human bone marrow stromal cells enhance breast cancer cell growth rates in a
cell line-dependent manner when evaluated in 3D tumor environments. Cancer
Lett 254: 255–264.
39. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, et al. (2007)
Interleukin-6 is a potent growth factor for ER-a-positive human breast cancer.
FASEB J 21: 3763–3770.
40. Bae S, Park CW, Son HK, Ju HK, Paik D, et al. (2008) Fibroblast activation
protein a identifies mesenchymal stromal cells from human bone marrow.
Br J Haematol 142: 827–830.
41. Littlepage LE, Egeblad M, Werb Z (2005) Coevolution of cancer and stromal
cellular responses. Cancer Cell 7: 499–500.
42. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392–401.
43. Lazarides E, Granger BL, Gard DL (1982) Desmin- and vimentin-containing
filaments and their role in the assembly of the Z disk in muscle cells. COLD
SPRING HARBOR SYMP QUANT BIOL 46: 351–378.
44. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, et al. (2004)
Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem
Cells 22: 377–384.
45. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, et al. (1999)
Vascular channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol 155: 739–752.
46. Ilan N, Madri JA (2003) PECAM-1: Old friend, new partners. Curr Opin Cell
Biol 15: 515–524.
47. Harrison P, Bradley L, Bomford A (2000) Mechanism of regulation of HGF/SF
gene expression in fibroblasts by TGF-b1. Biochem Biophys Res Commun 271:
203–211.
48. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, et al. (2005) Profiling
molecular targets of TGF-b1 in prostate fibroblast-to- myofibroblast transdiffer-
entiation. Mech Ageing Dev 126: 59–69.
49. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, et al. (2008) Silencing
the MET oncogene leads to regression of experimental tumors and metastases.
Oncogene 27: 684–693.
50. Labelle M, Schnittler HJ, Aust DE, Friedrich K, Etton G, et al. (2008) Vascular
endothelial cadherin promotes breast cancer progression via transforming
growth factor b signaling. Cancer Res 68: 1388–1397.
51. Yang F, Strand DW, Rowley DR (2008) Fibroblast growth factor-2 mediates
transforming growth factor-B action in prostate cancer reactive stroma.
Oncogene 27: 450–459.
52. Matsumoto Y, Motoki T, Kubota S, Takigawa M, Tsubouchi H, et al. (2008)
Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic
acid. Biochem Biophys Res Commun 366: 110–116.
53. Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain
tumor growth and angiogenesis. Neuro-Oncology 7: 436–451.
54. Spix JK, Chay EY, Block ER, Klarlund JK (2007) Hepatocyte growth factor
induces epithelial cell motility through transactivation of the epidermal growth
factor receptor. Exp Cell Res 313: 3319–3325.
55. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, et al. (2004) Adult stem
cells from bone marrow (MSCs) isolated from different strains of inbred mice
vary in surface epitopes, rates of proliferation, and differentiation potential.
Blood 103: 1662–1668.
56. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, et al. (2007)
Tumor irradiation increases the recruitment of circulating mesenchymal stem
cells into the tumor microenvironment. Cancer Res 67: 11687–11695.
57. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development
of a self-inactivating lentivirus vector. J Virol 72: 8150–8157.
MSC Become TAF in Tumor
PLoS ONE | www.plosone.org 11 April 2009 | Volume 4 | Issue 4 | e4992